• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Dec. 3, 2012

View Archived Issues

BioCryst, Presidio 'Nuc' Tie; Plans Flu HAE but Fell Far

Investors must wait until a conference call later this week for full details, but the decision by BioCryst Pharmaceuticals Inc. and Presidio Pharmaceuticals Inc. to ditch their $101 million merger might seem almost inevitable, coming in the wake of problems for BioCryst's drug candidates in flu, hepatitis C virus (HCV) and hereditary angioedema. Read More

New Discoveries in Parkinson's Point to Biomarkers, Therapies

Although Parkinson's disease (PD) is estimated to be the second most common neurodegenerative disorder, very little is known about its underlying cause. That could be about to change as scientists continue to drill down into the molecular machinery implicated in the disease. Read More

Asceneuron Latest Ascension from Merck's Geneva Ashes

The third spin-off from the entrepreneurship partnership program (EPP) launched in April by Merck KGaA biopharmaceutical division Merck Serono SA in conjunction with the closure of its Geneva headquarters, Asceneuron SA is focusing on one of biotech's most elusive targets: Alzheimer's disease (AD). Read More

Exhausted T Cells Soldier on in the Chronic Infection Fight

If you have to run a marathon, do it as a relay. That, apparently, is the immune system's solution to dealing with chronic infections, a study published in the Nov. 30, 2012, issue of Science suggested. Read More

CBO: New Findings on Prescriptions, Medicare Spend

A report by the Congressional Budget Office (CBO) found that an increase in prescription use reduces Medicare spending on other health care services. Read More

Stock Movers

Read More

Financings Roundup

• Progenics Pharmaceuticals Inc., of Tarrytown, N.Y., priced its underwritten offering of 11 million shares at $2 per share, for gross proceeds of $22 million. Read More

Other News To Note

• Exelixis Inc., of South San Francisco, said the European Medicines Agency accepted for review the marketing authorization application for Cometriq (cabozantinib) for the proposed indication of progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC). Read More

Clinic Roundup

• Theravectys SAS, of Paris, was granted authorization by the National Security Agency for Medicines and Health Products in France and the Federal Agency for Medicines and Health Products in Belgium to launch a Phase I/II trial with its anti-HIV therapeutic vaccine candidate. Read More

Pharma: Other News To Note

• Eisai Inc., of Woodcliff Lake, N.J., said the FDA accepted for priority review Eisai's NDA for AcipHex Delayed-Release Sprinkle Capsules 5mg and 10mg for the proposed indication of healing of gastroesophageal reflux Disease (GERD), maintenance of healing of GERD and improvement of symptoms of GERD in children 1 to 11 years of age. Read More

Bench Press: BioWorld Looks at Translational Medicine

Scientists at the National Institutes of Health have discovered a role for SIRT-2 in programmed necrosis. The notion of programmed necrosis was once something of a contradiction in terms, with necrosis considered accidental, injury-induced cell death as opposed to the programmed cell death of apoptosis. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • DNA mutations or genetic disorder concept art

    Regenxbio’s Duchenne gene therapy data positive as shares falter

    BioWorld
    Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe